Key result
Hyperoside attenuates doxorubicin-induced cardiac dysfunction and apoptosis by inhibiting the NOXs/ROS/NLRP3 inflammasome.
Why the study?
Clinical application of doxorubicin in cancer chemotherapy is limited by cardiotoxicity, prompting investigation into the protective effect and mechanism of hyperoside.
Does hyperoside prevent doxorubicin-induced cardiotoxicity in preclinical models?
Does hyperoside prevent doxorubicin-induced cardiotoxicity in preclinical models?
Hyperoside shows promise as a therapeutic strategy for doxorubicin-induced cardiotoxicity by inhibiting the NOXs/ROS/NLRP3 inflammasome signaling pathway in preclinical models.
Shows promise in animal models; leaves open clinical translation for doxorubicin cardiotoxicity.
Clinical application of doxorubicin (Dox) in cancer chemotherapy is limited by its cardiotoxicity. Present study aimed to demonstrate the effect and mechanism of hyperoside in Dox-induced cardiotoxicity. C57BL/6 mice were injected with 12 mg/kg of Dox, and 1 μM Dox was exposed to primary cardiomyocytes. Cardiac function was evaluated by echocardiographic and myocardial enzyme levels. Cardiomyocyts apoptosis was analyzed by TUNEL staining and flow cytometry. Network pharmacology and molecular docking were utilized to explore potential targets of hyperoside. Protein expressions were detected by western blot and enzyme activities were determined by colorimetry. Cardiac dysfunction and cardiomyocyte apoptosis induced by Dox were attenuated by hyperoside. Mechanism of hyperoside was mainly related to "oxidative stress" pathway. Hyperoside exhibited strong binding activities with nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOXs, the main source of ROS in cardiomyocytes) and cyclooxygenases (COXs). Experiments proved that hyperoside suppressed the ROS generation and the elevated activities of NOXs and COXs induced by Dox. Dox also triggered the activation of NLRP3 inflammasome, which was reversed by hyperoside. Hyperoside bound to NOXs and COXs, which prevents Dox-induced cardiotoxicity by inhibiting NOXs/ROS/NLRP3 inflammasome signaling pathway. Hyperoside holds promise as a therapeutic strategy for Dox-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2023) studied Doxorubicin-induced cardiotoxicity. Hyperoside vs. Doxorubicin alone was evaluated on Cardiac dysfunction and cardiomyocyte apoptosis. Hyperoside attenuated doxorubicin-induced cardiac dysfunction and cardiomyocyte apoptosis by inhibiting the NOXs/ROS/NLRP3 inflammasome signaling pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: